Minireviews
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Psychiatry. Jun 19, 2025; 15(6): 105409
Published online Jun 19, 2025. doi: 10.5498/wjp.v15.i6.105409
Targeting muscarinic receptors in schizophrenia treatment: Novel antipsychotic xanomeline/trospium chloride
Ana V Pejčić
Ana V Pejčić, Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac 34000, Serbia
Author contributions: Pejčić AV was responsible for conception, design, literature search, formal analysis, drafting and editing of the manuscript, and approved the final manuscript. The author has read and approved the final manuscript.
Conflict-of-interest statement: Author declares no conflict of interests for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ana V Pejčić, PhD, Assistant Professor, Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovića 69, Kragujevac 34000, Serbia. anapejcic201502@yahoo.com
Received: January 21, 2025
Revised: April 4, 2025
Accepted: May 13, 2025
Published online: June 19, 2025
Processing time: 128 Days and 16.2 Hours
Core Tip

Core Tip: Xanomeline/trospium chloride is a potential new treatment option for a wide range of schizophrenia symptoms, offering a relatively favorable tolerability and safety profile. However, additional research is required to better understand its effectiveness and safety in real-world clinical practice, and to define its optimal role in managing this complex psychiatric disorder. As new evidence emerges, it is vital to evaluate it critically.